CAREDX INC (CDNA)
Health Care · Precision diagnostics / genomics-based molecular testing · NASDAQ
CareDx is the leading provider of genomics-based molecular diagnostics for transplant patients, combining non-invasive cell-free DNA and gene expression testing with digital health and patient solutions to improve transplant outcomes across heart, kidney, and lung.
What CAREDX INC does
CareDx is a precision medicine company that delivers genomics-based non-invasive molecular testing solutions for transplant patients, focused on heart, kidney, and lung transplants. The company offers integrated solutions including molecular diagnostic tests (AlloSure and AlloMap), laboratory products, digital health technologies, and patient management solutions that support care before and after organ transplant. CareDx generates revenue from testing services (78% of Q1 2026 revenue), laboratory products, and patient/digital solutions, serving transplant centers across the United States and Europe.
Themes: ["Precision medicine / genomics","Transplant diagnostics","Donor-derived cell-free DNA testing","Digital health / patient management","Organ transplant outcomes","Laboratory developed tests (LDT)"]
Fundamentals
- Price$29.11 as of 2026-07-09 close
- Market cap$1.4B as of 2026-07-10
- 1-year return+43.5% as of 2026-07-09 close
- Net margin-2.0% as of 2026-07-10
- Gross margin+68.9% as of 2026-07-10
- ROE-2.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+19.2% as of 2026-07-10
- Revenue CAGR (3y)+5.7% SEC XBRL
- Beta2.49 as of 2026-07-10
Key risks (from latest filing)
["Revenue depends on third-party payer coverage determination and reimbursement policies; inability to secure positive coverage decisions or collect from payers without coverage can materially impact revenue growth","Market adoption of molecular diagnostics is challenged by low switching costs and high revenue acquisition costs, making profitability difficult to achieve; CareDx is currently unprofitable with a -1.98% net margin despite 19% revenue growth","Competition from other molecular diagnostics providers and new entrants in the transplant testing market; success depends on clinical evidence generation, market share retention at transplant centers, and ability to cross-sell solutions"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.